Skip to Content

Revance Aesthetics

Revance is building a premium aesthetics category focused on differentiated products, improved outcomes, and an elevated experience for healthcare professionals (HCPs) and patients. It is anchored by two synergistic products: our lead investigational candidate DaxibotulinumtoxinA for Injection and TEOXANE’s RHA® dermal filler collection.

DaxibotulinumtoxinA for Injection is an investigational agent that has not been approved by the FDA. Anticipated approval in 2020.

Aesthetics

Facts, Figures & Trends

#1 + #2

Neuromodulators are the most performed minimally invasive cosmetic procedures, followed by dermal fillers1

2.6 million

Total facial injectable procedures performed in 20181

~2.2 billion

2019 U.S. facial aesthetics opportunity (neuromodulators and dermal fillers)2

DaxibotulinumtoxinA for Injection

Our investigational neuromodulator product, DaxibotulinumtoxinA for Injection, is aiming to establish a new, premium, long-lasting neuromodulator category.

Learn More

RHA® Resilient Hyaluronic Acid®

The first and only collection of FDA-approved dermal fillers for correction of moderate-to-severe dynamic facial wrinkles and folds.

Learn More

References

  1. The American Society of Plastic Surgeons. 2018 Plastic Surgery Statistic Report. Available at: https://www.plasticsurgery.org/documents/News/Statistics/2018/plastic-surgery-statistics-full-report-2018.pdf. Accessed July 2019
  2. Based on estimates from the USB Specialty Pharmaceuticals Handbook 2018

Career Opportunities

Do you have what it takes to join our team? Check out our Careers page and find out.

Learn More
Back to top